Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.
4-1BB
4-1BB ligand
CD137
CD137L
TNFRSF9
X-ray crystallography
cell surface receptor
immune cell
protein structure
protein–protein interaction
tumor necrosis factor (TNF)
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
08 02 2019
08 02 2019
Historique:
received:
17
10
2018
revised:
28
11
2018
pubmed:
14
12
2018
medline:
27
6
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
The interaction between the receptor 4-1BB and its ligand 4-1BBL provides co-stimulatory signals for T-cell activation and proliferation. However, differences in the mouse and human molecules might result in differential engagement of this pathway. Here, we report the crystal structure of mouse 4-1BBL and of the mouse 4-1BB/4-1BBL complex, which together provided insights into the molecular mechanism by which m4-1BBL and its cognate receptor recognize each other. Unlike all human or mouse tumor necrosis factor ligands that form noncovalent and mostly trimeric assemblies, the m4-1BBL structure formed a disulfide-linked dimeric assembly. The structure disclosed that certain differences in the amino acid composition along the intramolecular interface, together with two specific residues (Cys-246 and Ser-256) present exclusively in m4-1BBL, are responsible for this unique dimerization. Unexpectedly, upon m4-1BB binding, m4-1BBL undergoes structural changes within each protomer; moreover, the individual m4-1BBL protomers rotate relative to each other, yielding a dimerization interface with more inter-subunit interactions. We also observed that in the m4-1BB/4-1BBL complex, each receptor monomer binds exclusively to a single ligand subunit with contributions of cysteine-rich domain 1 (CRD1), CRD2, and CRD3. Furthermore, structure-guided mutagenesis of the binding interface revealed that novel binding interactions with the GH loop, rather than the DE loop, are energetically critical and define the m4-1BB receptor selectivity for m4-1BBL. A comparison with the human 4-1BB/4-1BBL complex highlighted several differences between the ligand- and receptor-binding interfaces, providing an explanation for the absence of inter-species cross-reactivity between human and mouse 4-1BB and 4-1BBL molecules.
Identifiants
pubmed: 30545939
pii: S0021-9258(20)36832-0
doi: 10.1074/jbc.RA118.006297
pmc: PMC6369289
doi:
Substances chimiques
4-1BB Ligand
0
Multiprotein Complexes
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Banques de données
PDB
['6D3N', '6MKB', '6MKZ', '5WI8']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1831-1845Subventions
Organisme : NIGMS NIH HHS
ID : P41 GM103393
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI110929
Pays : United States
Informations de copyright
© 2019 Bitra et al.
Références
J Biol Chem. 2018 Jan 26;293(4):1317-1329
pubmed: 29242193
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
PLoS One. 2011 Jan 14;6(1):e16129
pubmed: 21264248
Mol Cell Biol. 1998 Jan;18(1):558-65
pubmed: 9418902
J Immunol. 1998 Mar 1;160(5):2488-94
pubmed: 9498794
PLoS One. 2014 Jan 21;9(1):e86337
pubmed: 24466035
Trends Biochem Sci. 2002 Jan;27(1):19-26
pubmed: 11796220
Eur J Immunol. 2016 Mar;46(3):513-22
pubmed: 26773716
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19452-7
pubmed: 18040044
Cell. 2001 Feb 23;104(4):487-501
pubmed: 11239407
Eur J Immunol. 2008 Apr;38(4):1024-32
pubmed: 18395851
Eur J Immunol. 1994 Feb;24(2):367-74
pubmed: 8299685
Semin Immunol. 1998 Dec;10(6):481-9
pubmed: 9826581
J Biol Chem. 2018 Jun 29;293(26):9958-9969
pubmed: 29720398
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):641-5
pubmed: 18178614
Methods Enzymol. 2003;374:229-44
pubmed: 14696376
Trends Biochem Sci. 1998 Feb;23(2):74-9
pubmed: 9538693
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
J Immunol. 2015 Jan 1;194(1):134-41
pubmed: 25404362
EMBO J. 1999 Apr 15;18(8):2119-26
pubmed: 10205166
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):133-44
pubmed: 20124693
Immunol Rev. 2009 May;229(1):356-86
pubmed: 19426233
J Immunol. 1993 Feb 1;150(3):771-81
pubmed: 7678621
J Exp Med. 2014 Jun 30;211(7):1433-48
pubmed: 24958847
Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1131-7
pubmed: 12832755
J Biol Chem. 2011 Apr 1;286(13):11226-35
pubmed: 21285457
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1360-6
pubmed: 11567146
Structure. 2006 Aug;14(8):1321-30
pubmed: 16905106
J Biol Chem. 2018 Jun 22;293(25):9880-9891
pubmed: 29720399
Mol Cell. 1999 Oct;4(4):563-71
pubmed: 10549288
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):635-40
pubmed: 18182486
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Nat Med. 1997 Jun;3(6):682-5
pubmed: 9176498
J Immunol. 2012 Jul 1;189(1):245-52
pubmed: 22664871
J Biol Chem. 2010 Mar 19;285(12):9202-10
pubmed: 20032458
Immunol Rev. 2011 Nov;244(1):197-217
pubmed: 22017440
J Biol Chem. 2000 Oct 6;275(40):31171-7
pubmed: 10893238